5results about How to "Efficient infection" patented technology

The invention belongs to the technical field of gene engineering and biology, discloses a modified adeno-associated virus AAV-8 serotype for retina wide targeting and expression, and further relates to construction and application of the modified type. 10 amino acid sequences as shown in SEQ ID NO.3 are inserted between the 590th amino acid and the 591th amino acid of an AAV-8 serotype capsid protein sequence as shown in SEQ ID NO.2, the first, second and tenth amino acids are protected amino acids, and the third to ninth amino acids are amino acid sequences obtained by screening. The modified serotype disclosed by the invention is stronger in fluorescence effect after infection and can be obviously and intuitively observed, an exogenous gene can be widely and efficiently expressed in a specific targeted tissue retina whole region, and the expression efficiency is greatly improved under the condition of using the same virus amount. And compared with a wild serotype, the serotype has better and wider targeted tissue expression and less non-targeted tissue expression.

This invention belongs to the field of antimicrobial peptide technology, and particularly relates to a broad-spectrum antimicrobial peptide with low hemolytic activity and its applications, as well as a broad-spectrum antibacterial drug. The antimicrobial peptide is named AY6, and its amino acid sequence is shown in SEQ ID NO.1. Antimicrobial peptide AY6 exhibits significant antibacterial effects against both Gram-positive and Gram-negative bacteria, with a bactericidal rate far exceeding that of traditional antibiotics, enabling highly effective responses to bacterial infections. AY6 has low hemolytic activity and good biocompatibility, making it suitable for medical anti-infective applications. The antimicrobial peptide provided in this application has a short sequence, is easy to synthesize chemically, can save on large-scale production costs, and has broad application prospects.

The application discloses a kind of construction methods of mouse placenta targeted gene interference model and its application.The method comprises the following steps: first, pregnant mouse is anaesthetized and abdominal operation is carried out, and the uterus containing placenta is exposed;Then, the adeno-associated virus carrying gene interference element is directly injected into target placental tissue;Finally, the wound is sutured to complete model construction.The present application overcomes the problem of low virus delivery efficiency caused by maternal-fetal barrier by intraoperative direct site injection, and realizes the efficient and specific gene interference of placental tissue.The model constructed is targeted and precise, has high interference efficiency and low off-target effect, and provides an effective tool for studying placental gene function and pregnancy-related diseases.

The invention provides application of Senecavirus A in preparation of a medicine for preventing and / or treating oral cancer, and particularly belongs to the technical field of medicine. The invention provides and verifies application of Senecavirus A in preparation of drugs for preventing and / or treating oral cancer. Specifically, in-vitro and in-vivo test results show that the Seneca virus A disclosed by the invention can realize prevention and / or treatment of oral squamous cell carcinoma.

The present invention discloses a technical field involving antibiotic enzymes, and in particular, relates to a hybrid antibiotic enzyme for killing animal-derived pathogens and its application. The hybrid antibiotic enzyme includes a hybrid protein E1C1, and the hybrid protein E1C1 includes a catalytic domain E1 as shown in SEQ ID NO:2 and a binding domain C1 as shown in SEQ ID NO:3. The present invention also provides an application of a hybrid antibiotic enzyme in the preparation of a pharmaceutical composition for controlling microbial infection, and a pharmaceutical composition comprising the hybrid antibiotic enzyme as an effective ingredient. The hybrid antibiotic enzyme of the present application can quickly lyse common animal-derived pathogens Escherichia coli, Salmonella, Staphylococcus aureus and Helicobacter pylori, and can also efficiently kill common pathogens such as clinically isolated Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae.